已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

医学 T790米 内科学 肿瘤科 表皮生长因子受体 肺癌 腺癌 癌症 癌症研究 吉非替尼
作者
Nicolas Marcoux,Scott Gettinger,Grainne M. O’Kane,Kathryn C. Arbour,Joel W. Neal,Hatim Husain,Tracey L. Evans,Julie R. Brahmer,Alona Muzikansky,Philip Bonomi,Salvatore Del Prete,Anna Wurtz,Anna F. Farago,Dora Dias‐Santagata,Mari Mino‐Kenudson,Karen L. Reckamp,Helena A. Yu,Heather A. Wakelee,Frances A. Shepherd,Zofia Piotrowska
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:37 (4): 278-285 被引量:365
标识
DOI:10.1200/jco.18.01585
摘要

Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformation to small-cell lung cancer (SCLC), but their clinical course is poorly characterized.We retrospectively identified patients with EGFR-mutant SCLC and other high-grade neuroendocrine carcinomas seen at our eight institutions. Demographics, disease features, and outcomes were analyzed.We included 67 patients-38 women and 29 men; EGFR mutations included exon 19 deletion (69%), L858R (25%), and other (6%). At the initial lung cancer diagnosis, 58 patients had NSCLC and nine had de novo SCLC or mixed histology. All but these nine patients received one or more EGFR tyrosine kinase inhibitor before SCLC transformation. Median time to transformation was 17.8 months (95% CI, 14.3 to 26.2 months). After transformation, both platinum-etoposide and taxanes yielded high response rates, but none of 17 patients who received immunotherapy experienced a response. Median overall survival since diagnosis was 31.5 months (95% CI, 24.8 to 41.3 months), whereas median survival since the time of SCLC transformation was 10.9 months (95% CI, 8.0 to 13.7 months). Fifty-nine patients had tissue genotyping at first evidence of SCLC. All maintained their founder EGFR mutation, and 15 of 19 with prior EGFR T790M positivity were T790 wild-type at transformation. Other recurrent mutations included TP53, Rb1, and PIK3CA. Re-emergence of NSCLC clones was identified in some cases. CNS metastases were frequent after transformation.There is a growing appreciation that EGFR-mutant NSCLCs can undergo SCLC transformation. We demonstrate that this occurs at an average of 17.8 months after diagnosis and cases are often characterized by Rb1, TP53, and PIK3CA mutations. Responses to platinum-etoposide and taxanes are frequent, but checkpoint inhibitors yielded no responses. Additional investigation is needed to better elucidate optimal strategies for this group.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
H_不甜也是糖完成签到 ,获得积分10
1秒前
激动的访文应助Colo采纳,获得30
2秒前
瑶啊瑶完成签到,获得积分10
3秒前
欢喜妙旋发布了新的文献求助10
3秒前
3秒前
8秒前
9秒前
干净初彤发布了新的文献求助10
10秒前
欢喜妙旋完成签到,获得积分10
11秒前
Ava应助科研通管家采纳,获得10
12秒前
CipherSage应助科研通管家采纳,获得10
12秒前
12秒前
12秒前
HZHZHZ完成签到 ,获得积分10
12秒前
皮皮蛙发布了新的文献求助10
13秒前
安然发布了新的文献求助10
14秒前
执着南琴发布了新的文献求助20
15秒前
机灵白桃关注了科研通微信公众号
18秒前
20秒前
CHAYA发布了新的文献求助10
22秒前
日出完成签到,获得积分10
25秒前
可靠一德发布了新的文献求助10
26秒前
安然发布了新的文献求助10
29秒前
miabb关注了科研通微信公众号
31秒前
33秒前
Monster完成签到,获得积分10
35秒前
1820877108发布了新的文献求助10
36秒前
37秒前
羊羊完成签到 ,获得积分10
38秒前
调研昵称发布了新的文献求助10
38秒前
攀攀完成签到,获得积分10
38秒前
二毛完成签到 ,获得积分10
38秒前
40秒前
顾矜应助QQQ采纳,获得20
40秒前
40秒前
41秒前
yixueshng完成签到 ,获得积分10
43秒前
ZXG发布了新的文献求助10
46秒前
miabb发布了新的文献求助10
46秒前
48秒前
高分求助中
Continuum thermodynamics and material modelling 3000
Production Logging: Theoretical and Interpretive Elements 2500
Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation 2000
Applications of Emerging Nanomaterials and Nanotechnology 1111
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Theory of Block Polymer Self-Assembly 750
지식생태학: 생태학, 죽은 지식을 깨우다 700
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3484176
求助须知:如何正确求助?哪些是违规求助? 3073236
关于积分的说明 9130199
捐赠科研通 2764925
什么是DOI,文献DOI怎么找? 1517450
邀请新用户注册赠送积分活动 702131
科研通“疑难数据库(出版商)”最低求助积分说明 701095